<DOC>
	<DOCNO>NCT02072330</DOCNO>
	<brief_summary>The objective study compare efficacy safety combine administration TAK-536CCB ( Fix-dose combination Azilsartan Amlodipine ) Hydrochlorothiazide ( HCTZ ) TAK-536CCB patient Grade I II essential hypertension .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Combined Administration TAK-536CCB Hydrochlorothiazide Patients With Grade I II Essential Hypertension .</brief_title>
	<detailed_description>This study randomize , double-blind , multicenter , phase 2/3 study evaluate efficacy safety combine administration TAK-536CCB Hydrochlorothiazide ( HCTZ ) TAK-536CCB Hydrochlorothiazide patient grade I II essential hypertension . This study consist 4-week single-blind placebo run-in period 10-week double-blind treatment period .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Grade I II essential hypertension . 2 . An office sit systolic blood pressure ≥ 150 &lt; 180 mmHg , office sit diastolic blood pressure ≥ 95 &lt; 110 mmHg placebo runin period Week −2 Week 0 . 3 . Male female age 20 year old time provide informed consent . 4 . Outpatient . 1 . Secondary hypertension , grade III hypertension malignant hypertension . 2 . An office sit systolic blood pressure ≥160 mmHg sit diastolic blood pressure ≥100 mmHg record combined therapy 3 antihypertensive within 4 week prior initiation placebo runin period Week −4 . 3 Evident white coat hypertension white coat phenomenon . 4 . Daynight reverse lifestyle , nighttime worker . 5 . Sleep apnea syndrome requiring treatment . 6 . Have cardiovascular disease symptom list : Heart disease : myocardial infarction ( within 24 week placebo runin period ) , coronary arterial revascularization ( within 24 week placebo runin period ) , severe valvular disease , atrial fibrillation , follow disease require medication : angina pectoris , congest heart failure , arrhythmia . Cerebrovascular disease : cerebral infarction , cerebral hemorrhage ( within 24 week placebo runin period ) , transient ischemic attack ( within 24 week placebo runin period ) . Vascular disease : peripheral arterial disease intermittent claudication , artery dissection , aneurysm Advanced hypertensive retinopathy : bleeding , exudation , papilledema ( within 24 week placebo runin period ) . 7 . Clinically significant hepatic disorder . 8 . Clinically significant renal impairment . 9 . Significantly low high Potassium Sodium level . 10 . Complicated gout , past history gout within 24 week prior initiation placebo runin period , complicate hyperuricemia require medication . 11 . Diabetic subject insulin treatment poorly control type 2 diabetes mellitus . 12 . Have malignant tumor .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Hypertension , Drug therapy</keyword>
</DOC>